Literature DB >> 9135220

Late onset spondylarthropathy: clinical and biological comparison with early onset patients.

D Caplanne1, F Tubach, J M Le Parc.   

Abstract

OBJECTIVE: To compare the clinical, radiological, and biological profile of patients presenting late onset spondylarthropathy (LOSPA) with patients with early onset spondylarthropathy (EOSPA).
METHODS: During the period April 1987 to April 1995 a retrospective chart review of inpatients and outpatients identified eight patients with LOSPA. They were matched with 32 patients with EOSPA examined during the same period of time. Clinical, radiological, and biological signs were compared. All patients fulfilled Amor criteria for spondylarthropathy.
RESULTS: Mean age of patients with LOSPA was 65.1 years (range 58-72), and 26.6 years (range 11-40) in patients with EOSPA. The sex ratio (female/male) was 5/3 in LOSPA and 9/23 in EOSPA (p = 0.007). Patients with LOSPA had more significantly cervical and dorsal pain (p = 0.002, p = 0.02 respectively), anterior chest wall involvement (p = 0.04), number of peripheral arthritis (p = 0.04), aseptic osteitis (p = 0.004), and systemic symptoms: fever, fatigue, weight loss (p = 0.04). Mean (SD) erythrocyte sedimentation rate was 87 (24) in LOSPA and 24 (35) in EOSPA patients (p = 0.001). Inflammatory bowel disease was diagnosed in three patients with EOSPA. A definite family history of SPA was found in 50% of patients with LOSPA and in 31% of patients with EOSPA. A clear response to NSAID was obtained in 62% of LOSPA patients and in 90.6% of EOSPA patients (p = 0.05). Three LOSPA patients (two with Crohn's disease) not responding to NSAID were successfully treated with prednisone.
CONCLUSION: The onset of spondylarthropathy is uncommon after 55 years. Patients with LOSPA, according to accepted international criteria present a different clinical and biological profile when compared with younger patients. These results suggests that age may influence the presentation of SPA at onset.

Entities:  

Mesh:

Year:  1997        PMID: 9135220      PMCID: PMC1752337          DOI: 10.1136/ard.56.3.176

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  13 in total

1.  Long term safety of etanercept in elderly subjects with rheumatic diseases.

Authors:  R Fleischmann; S W Baumgartner; M H Weisman; T Liu; B White; P Peloso
Journal:  Ann Rheum Dis       Date:  2005-09-08       Impact factor: 19.103

Review 2.  Spondyloarthritis with onset after age 45.

Authors:  Ignazio Olivieri; Salvatore D'Angelo; Angela Padula; Pietro Leccese; Carlo Palazzi
Journal:  Curr Rheumatol Rep       Date:  2013-12       Impact factor: 4.592

3.  Demographic, clinical, and laboratory features of Turkish patients with late onset ankylosing spondylitis.

Authors:  Ahmet Karaarslan; Hatice Yilmaz; Hakan Aycan; Mehmet Orman; Senol Kobak
Journal:  Bosn J Basic Med Sci       Date:  2015-07-22       Impact factor: 3.363

4.  Clinical and laboratory manifestations of elderly onset psoriatic arthritis: a comparison with younger onset disease.

Authors:  L Punzi; M Pianon; P Rossini; F Schiavon; P F Gambari
Journal:  Ann Rheum Dis       Date:  1999-04       Impact factor: 19.103

Review 5.  Late-onset ankylosing spondylitis and spondylarthritis: an update on clinical manifestations, differential diagnosis and pharmacological therapies.

Authors:  Eric Toussirot
Journal:  Drugs Aging       Date:  2010-07-01       Impact factor: 3.923

6.  Late onset spondyloarthropathy mimicking polymyalgia rheumatica.

Authors:  Ali Aydeniz; Ozlem Altındağ; Evrim Oğüt; Savaş Gürsoy
Journal:  Rheumatol Int       Date:  2010-03-18       Impact factor: 2.631

Review 7.  Diagnosis and Management of Late-Onset Spondyloarthritis: Implications of Treat-to-Target Recommendations.

Authors:  Éric Toussirot
Journal:  Drugs Aging       Date:  2015-07       Impact factor: 3.923

Review 8.  Late-onset ankylosing spondylitis and related spondylarthropathies: clinical and radiological characteristics and pharmacological treatment options.

Authors:  Eric Toussirot; Daniel Wendling
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 9.  Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis.

Authors:  Roy Fleischmann; Imran Iqbal
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 10.  Late-Onset and Elderly Psoriatic Arthritis: Clinical Aspects and Management.

Authors:  Francesco Caso; Marco Tasso; Maria Sole Chimenti; Luca Navarini; Carlo Perricone; Nicolò Girolimetto; Rosario Peluso; Antonio Del Puente; Antonella Afeltra; Roberto Perricone; Leonardo Punzi; Raffaele Scarpa; Luisa Costa
Journal:  Drugs Aging       Date:  2019-10       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.